Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report

Fig. 1

Brain MRI showing the response and the progression of the leptomeningeal disease with BRAF inhibitor-based therapy. The arrows indicate the enhancement of the leptomeninges in April 2013. After vemurafenib therapy, the follow-up images revealed initial regression of the leptomeningeal disease. He had progression of the leptomeningeal disease in October 2013 and started whole brain radiation followed by dabrafenib plus trametinib. The follow-up scans showed regressed leptomeningeal disease

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us